Natco Pharma Limited has intimated the stock exchanges about an upcoming Board of Directors meeting scheduled for August 14, 2026. This meeting is being convened specifically to consider and evaluate proposals for raising funds through various methods of capital issuance.
The fundraising may be conducted through issuance of equity shares or other securities, including by way of:
- Public issue
- Preferential issue
- Rights issue
- Private placement(s)
- Qualified institutions placement(s)
- Any combination of the above methods
- Any other method permitted under applicable laws
The company explicitly states that any fundraising activity will be subject to market conditions and receipt of all necessary regulatory, statutory, and other approvals as may be required. This intimation is made pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, and references an earlier board meeting intimation dated August 6, 2026.
Financial Impact
Financial impact not quantified in the disclosure. The nature of the fundraising and specific amounts have not been determined as the Board is yet to evaluate the proposals.